How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.
Louis Cicchini, PhD, and Michael Day, PhD
Advertisement
Articles by Louis Cicchini, PhD, and Michael Day, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees
2
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
3
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
4
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees
5